Zacks Research Lifts Earnings Estimates for Teladoc Health

Teladoc Health, Inc. (NYSE:TDOC) – Research analysts at Zacks Research lifted their FY2024 earnings per share estimates for shares of Teladoc Health in a note issued to investors on Wednesday, November 13th. Zacks Research analyst R. Department now forecasts that the health services provider will post earnings per share of ($1.15) for the year, up from their prior estimate of ($1.31). The consensus estimate for Teladoc Health’s current full-year earnings is ($1.17) per share. Zacks Research also issued estimates for Teladoc Health’s Q4 2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($1.05) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.89) EPS.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.10. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. The business had revenue of $640.51 million during the quarter, compared to analyst estimates of $630.50 million.

A number of other equities research analysts have also recently issued reports on the stock. The Goldman Sachs Group initiated coverage on shares of Teladoc Health in a research note on Friday. They issued a “buy” rating and a $14.00 price objective for the company. Jefferies Financial Group raised their price objective on Teladoc Health from $8.00 to $10.00 and gave the company a “hold” rating in a research note on Tuesday, September 17th. JPMorgan Chase & Co. lowered their target price on Teladoc Health from $16.00 to $9.00 and set a “neutral” rating for the company in a research note on Monday, August 26th. TD Cowen dropped their target price on Teladoc Health from $9.00 to $8.00 and set a “hold” rating for the company in a report on Thursday, October 31st. Finally, Barclays lifted their price target on Teladoc Health from $10.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Fourteen analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $12.08.

Teladoc Health Stock Up 2.8 %

Shares of TDOC opened at $9.21 on Monday. Teladoc Health has a 1 year low of $6.76 and a 1 year high of $22.54. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.73 and a quick ratio of 1.69. The stock has a 50 day simple moving average of $8.89 and a two-hundred day simple moving average of $9.36. The firm has a market cap of $1.59 billion, a P/E ratio of -1.60 and a beta of 0.90.

Insider Transactions at Teladoc Health

In other news, CFO Mala Murthy sold 8,750 shares of Teladoc Health stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total value of $62,650.00. Following the completion of the transaction, the chief financial officer now owns 85,767 shares of the company’s stock, valued at $614,091.72. The trade was a 9.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas Mckinley acquired 4,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average cost of $7.69 per share, for a total transaction of $30,760.00. Following the completion of the transaction, the director now directly owns 39,077 shares in the company, valued at $300,502.13. The trade was a 11.40 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 20,051 shares of company stock valued at $143,565 in the last three months. 0.95% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Point72 Asset Management L.P. grew its holdings in shares of Teladoc Health by 57.8% during the third quarter. Point72 Asset Management L.P. now owns 8,366,295 shares of the health services provider’s stock valued at $76,803,000 after buying an additional 3,063,172 shares during the last quarter. Rubric Capital Management LP bought a new position in Teladoc Health in the 2nd quarter valued at approximately $45,267,000. Clearline Capital LP boosted its stake in Teladoc Health by 395.6% during the 2nd quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after purchasing an additional 3,483,665 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Teladoc Health by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 3,925,167 shares of the health services provider’s stock worth $36,042,000 after purchasing an additional 56,864 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in shares of Teladoc Health during the third quarter valued at $15,801,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.